Axonis Therapeutics
PrivateLast Round
Series A
Oct 30, 2024
Total Funding Raised
$141.7M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Axonis Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in October 2024.
Axonis Therapeutics is a biotechnology company developing first-in-class oral small molecule therapies targeting KCC2 to treat central nervous system disorders such as epilepsy, chronic pain, and spinal cord injuries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Axonis Therapeutics Comparables
Compare Axonis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IAMA Therapeutics | 81% | |
| Leal Therapeutics | 80% | |
| NovaGo Therapeutics | 79% |
For institutional investors. Book with your work email.
Axonis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 30, 2024 | ||||
| Grant | Sep 1, 2024 | ||||
| Seed | Jul 14, 2021 | ||||
| Seed | May 28, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Axonis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Biomedical Imaging and Bioengineering | Seed |
| Iaso Ventures | Series A |
| SCI Ventures | Series A |
| CURE Epilepsy | Grant |
| Perceptive Advisors | Series A |
| Acks | Series A |
| NIH RADx | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 44% MoM.
- Oct 15, 2025
Translating discoveries from Boston Children's Hospital, Harvard, and Laval University.
For institutional investors. Book with your work email.
Axonis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Axonis Therapeutics's valuation, stock price, and market status.
Is Axonis Therapeutics a public or private company?
Axonis Therapeutics is a private company.
What is the current stock price of Axonis Therapeutics?
Axonis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Axonis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Axonis Therapeutics worth (valuation)?
Valuation information for Axonis Therapeutics is not publicly available.
Can I buy Axonis Therapeutics stock?
Axonis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Axonis Therapeutics's last funding round?
Axonis Therapeutics's most recent funding round was Series A on October 30, 2024.
Who are the main investors in Axonis Therapeutics?
Key investors in Axonis Therapeutics include National Institute of Biomedical Imaging and Bioengineering, Cormorant Asset Management, Alexandria Venture Investments, venBio, Cormorant Asset Management.
Will Axonis Therapeutics IPO soon?
No public IPO plans have been announced for Axonis Therapeutics.
How can I track Axonis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Axonis Therapeutics's shares on secondary markets.